Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
HP Version - Clinical trials have complex eligibility criteria.Always talk to your clinician about you’re interest in participating in a trial.Learn why
Optimise reading forHealth ProfessionalsPatients
Closed (no longer recruiting)Last updated: 9 January 2024
Clinical summaryEligibilityParticipating hospitalsSupport
This trial contains two parts: dose escalation and dose expansion. Eligible patients will receive intravenous ABBV-467, either at a variable or recommended dose, depending on the part to which they are allocated.
This trial is treating patients with multiple myeloma.
Haematological
18+
I
M19-025
Use the hyperlinks, where available to access additional clinical trial information.
AbbVie
A First In Human Study of the MCL-1 Inhibitor, ABBV-467
Share with email
Print this page
Download brochure
Measurable disease defined as at least 1 of the following:
Clinical trials have complex eligibility criteria.
Ask your doctor if this trial could be right for you.
+ Show non-recruiting hospitals
Tell us if you find this trial availability is not accurate.Report inaccuracy
Speak with someone who has cancer clinical trial experience.
Learn more
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
Thank you for helping us to increase accuracy of the trial. Our team will validate the information and update the information as soon as possible.